 |
|
Colon and Rectal Cancer Trial Results
1. Combining Targeted Drugs Is Worse in Colorectal Cancer
(Posted: 02/24/2009) - A clinical trial testing chemotherapy combined with bevacizumab (Avastin) and cetuximab (Erbitux), and comparing this with chemotherapy and bevacizumab alone, found that the addition of cetuximab was actually worse for patients, according to the Feb. 5, 2009, New England Journal of Medicine.
2. 5-FU-Based Chemotherapy Cures Some Patients with Colon Cancer
(Posted: 02/03/2009) - Researchers from the Adjuvant Colon Cancer Endpoints (ACCENT) Group used individual patient data from 18 phase III trials of adjuvant 5-FU-based chemotherapy for colon cancer to show that the regimens provide their survival benefit primarily by reducing the high risk of recurrence within the first two years after surgery, according to a study published online January 5, 2009, in the Journal of Clinical Oncology.
3. Colorectal Cancer Trials Support Gene Testing for Two Drugs
(Posted: 11/12/2008) - A trio of 2008 studies adds to the growing evidence that patients with colorectal cancer should have their tumors tested for genetic mutations prior to starting therapy with cetuximab (Erbitux) or panitumumab (Vectibix).
4. Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy
(Posted: 09/17/2008) - Computerized tomographic colonography, also known as virtual colonoscopy, is comparable to standard colonoscopy, which uses a long, flexible tube with a camera to view the lining of the colon, in its ability to accurately detect cancer and precancerous polyps and could serve as an initial screening exam for colorectal cancer, according to the results of the American College of Radiology Imaging Network National CT Colonography Trial.
5. Colorectal Cancer Drugs Require Careful Patient Selection
(Posted: 06/18/2008) - Patients with advanced colorectal cancer who have mutant forms of the gene KRAS in their tumors should not receive chemotherapy plus cetuximab (Erbitux), because they are unlikely to benefit from the treatment, according to findings presented at the 2008 ASCO meeting in Chicago.
1 2 3 4 Next >
|
|
|
